July 20, 2020 / 6:13 AM / 16 days ago

BRIEF-GSK To Invest 130 Mln Stg In CureVac Under New Collaboration

July 20 (Reuters) - GlaxoSmithKline Plc:

* GSK AND CUREVAC ENTER COLLABORATION

* GSK TO MAKE EQUITY INVESTMENT OF £130M (EUR 150M) IN CUREVAC, AND AN UPFRONT PAYMENT OF £104M (EUR 120M)

* COMPANIES TO COLLABORATE ON MRNA VACCINE AND MONOCLONAL ANTIBODY RESEARCH PROGRAMMES IN INFECTIOUS DISEASES

* CUREVAC WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS OF UP TO £277M (EUR 320M)

* COMPANIES TO COLLABORATE ON MRNA VACCINE AND MONOCLONAL ANTIBODY RESEARCH PROGRAMMES IN INFECTIOUS DISEASES

* CUREVAC WILL BE ELIGIBLE TO RECEIVE DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS OF UP TO £277M (EUR 320M)

* GSK WILL FUND RESEARCH AND DEVELOPMENT ACTIVITIES AT CUREVAC RELATED TO DEVELOPMENT PROJECTS COVERED BY COLLABORATION

* WILL MAKE AN EQUITY INVESTMENT IN CUREVAC OF £130M (EUR 150M), REPRESENTING CLOSE TO A 10% STAKE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below